-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Public Health and Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience powered by Apple
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Environmental Social Governance
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions powered by Apple
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSBlog
Pediatric Studies Impact of Brexit on your Pediatric Investigational Plans (PIP)
May 09, 2019
The uncertainty of Brexit has significant implications for all aspects of product development and Pediatric Investigational Plans (PIPs) are no exception. The recently posted MHRA Guidance: Procedures for UK-PIPs in the event the UK leaves the EU without a deal provides some clarification and states that “UK aims to simplify the PIP application process for applicants by offering an expedited assessment where possible”. However, the overall impact is that there is an additional step of submission of a PIP to MHRA in addition to the submission to EMA, thus adding an additional application to an already complex and lengthy process of PIP preparation and submission.
To successfully navigate this road, pharma companies often seek assistance from a partner with a specialized mix of scientific, therapeutic, regulatory and operational expertise with the aim of ensuring their pediatric studies are successfully designed, planned and executed – with patient safety as the centerpiece of the program.
To address this expanding need, IQVIA has put together a team of experts with backgrounds in pediatric drug development, regulatory, modeling and simulation and pharmacokinetics (PK), to assist clients in the evaluation of their products or programs and recommend practical and informed strategies for pediatric drug development. Our team can evaluate client product profile(s) using a formalized methodology based on the Guidances of major regulatory agencies such as EMA and FDA, but also taking in consideration other Health Authority requirements. Our pediatric evaluation team will assess each unique scenario to determine whether the client will: a) need to develop a full Pediatric Investigational Plan; or b) potentially be eligible for a waiver or deferral. We are familiar not only with the unique challenges and principles inherent in pediatric trials but can leverage the specific therapeutic area background needed to provide customers with product specific advice targeted to their compounds. We can assist with coordination of a PIP and the Pediatric Study Plan if FDA submission is also being planned. Finally, we can also assist with PIP Modifications that may be needed as well as the final PIP Compliance Check that is required prior to the submission of the Marketing Authorisation Application.
A consultation from IQVIA can save clients significant time and expense by providing an intensive and independent pre-review based on regulatory requirements. If this review suggests a waiver is likely to be granted, IQVIA can provide a written justification in submission-ready format. If IQVIA’s review suggests a waiver is not likely to be granted, we can assist as needed in developing a Pediatric Investigational Plan/ Study Plan.
As this requirement applies to any new medicinal product that is seeking marketing authorization approval in the UK, it has significant implications for drug developers. It is important to facilitate discussion about pediatric development plans early on in the product’s development lifecycle, ideally following human PK studies.
Please contact us at: RareDisease_PediatricCOE@iqvia.com